|
Originally published In Press as doi:10.1074/jbc.M002424200 on August 10, 2000
J. Biol. Chem., Vol. 275, Issue 45, 35522-35531, November 10, 2000
Mutational Analysis of 3' Splice Site Selection during
trans-Splicing*
Heidi S.
Hummel ,
R. Dean
Gillespie§, and
John
Swindle ¶
From the Department of Microbiology and Immunology, University of
Tennessee, Memphis, Tennessee 38163
Received for publication, March 22, 2000, and in revised form, August 10, 2000
 |
ABSTRACT |
trans-Splicing is essential for
mRNA maturation in trypanosomatids. A conserved AG dinucleotide
serves as the 3' splice acceptor site, and analysis of native
processing sites suggests that selection of this site is determined
according to a 5'-3' scanning model. A series of stable gene
replacement lines were generated that carried point mutations at or
near the 3' splice site within the intergenic region separating
CUB2.65, the calmodulin-ubiquitin associated gene, and
FUS1, the ubiquitin fusion gene of Trypanosoma cruzi. In one stable line, the elimination of the native 3'
splice acceptor site led to the accumulation of Y-branched splicing
intermediates, which served as templates for mapping the first
trans-splicing branch points in T. cruzi. In
other lines, point mutations shifted the position of the first
consensus AG dinucleotide either upstream or downstream of the
wild-type 3' splice acceptor site in this intergenic region. Consistent
with the scanning model, the first AG dinucleotide downstream of the
branch points was used as the predominant 3' splice acceptor site. In
all of the stable lines, the point mutations affected splicing
efficiency in this region.
 |
INTRODUCTION |
trans-Splicing is an RNA processing event that was
first discovered in trypanosomatids and later observed in nematodes,
trematodes, and Euglena (1, 2). In all of these organisms,
this intermolecular process results in a spliced leader sequence at the
5'-end of mature transcripts. In trypanosomes, its importance has been
recognized for two reasons. First, the spliced leader supplies an
identical 5' terminal cap for every known messenger RNA (3), and
second, trans-splicing provides a means to convert
polycistronic pre-mRNA to monogenic mRNA (4).
Because trans-splicing joins segments of two independently
transcribed RNA molecules, it is distinct from cis-splicing,
an intramolecular process that removes introns separating
protein-coding sequences on primary transcripts. However,
trans-splicing does have a number of characteristics that
suggest that it is related to the more widely studied
cis-splicing. Mechanistically, both types of splicing occur
through similar steps, which are catalyzed by a spliceosome (5-8).
Also, some of the cis-acting sequences in
trans-splicing are identical to those observed in
cis-splicing (9, 10).
The trans-splicing reaction essentially occurs through two
steps and requires two RNA molecules, the spliced leader RNA carrying the spliced leader sequence and spliced leader intron and the pre-mRNA carrying a 5'-untranslated region followed by the protein coding sequence (7, 8, 11). The first step of the reaction is a
cleavage at the 5' splice donor site on the spliced leader RNA and the
simultaneous formation of a Y-branched intermediate. A 2'-5'
phosphodiester linkage between the first nucleotide at the 5'-end of
the spliced leader intron, a guanosine, and an internal adenosine
residue (the branch point) upstream of the 3' splice site of the
pre-mRNA characterizes this branched intermediate. During the
second step of trans-splicing, the Y-branched intermediate is removed when the spliced leader sequence is ligated to the pre-mRNA at the 3' splice site. Under most circumstances, this reaction is rapid, perhaps occurring co-transcriptionally. The precursors and intermediates are transient, and the functional end
products, mature mRNAs each carrying the capped spliced leader sequence, are the only steady-state RNA detected.
In trypanosomes, the disruption of open reading frames during
trans-splicing is avoided through the use of specific 3'
splice sites upstream of the translation initiation site of a
transcript. The locations of these splice sites as well as the branch
point sites are determined by the cis-acting sequences on
the pre-mRNA. Although these sequences have not been thoroughly
investigated, a few important elements have been recognized. The 3'
splice acceptor site always occurs at an AG dinucleotide, the consensus
sequence also used during cis-splicing (1). Polypyrimidine
tracts play an important role, since the elimination or successive
deletion of the polypyrimidine tracts near native 3' splice acceptor
sites often leads to activation of cryptic splice sites or diminished splicing within an intergenic region (12-15). Very little is known about the selection of the branch point site during
trans-splicing. The only branch points that have been mapped
are those for the highly expressed  and  tubulin transcripts
of Trypanosoma brucei (16). Although branching was shown to
occur at one or more A nucleotides upstream of the polypyrimidine
tracts associated with the tubulin 3' splice acceptor sites, no
consensus branch site sequence was determined.
The present study was initiated to develop a better understanding of
the cis-acting sequences near the 3' splice acceptor site
that are involved in trans-splicing. The noncoding sequence separating the 2.65 calmodulin-ubiquitin associated
(CUB2.65) and FUS1 ubiquitin fusion genes of the
calmodulin-ubiquitin complex of Trypanosoma cruzi presented
an ideal environment to analyze the effects of 3' splice acceptor site
mutations (see Fig. 1 and Ref. 17).
trans-Splicing of the FUS1 transcript occurs
quantitatively at the first and only AG dinucleotide between the
polypyrimidine tract and the FUS1 translation initiation
codon (18).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
The F intergenic region. The 362-bp
CUB2.65 to FUS1 (F) intergenic sequence
(GenBankTM accession number L01583) fused to the first 30 bp of the CAT (above) and
Neor (below) genes. The sequence is
numbered from the first nucleotide of the translation initiation codon
of the protein coding sequence. The wild-type splice acceptor site for
the FUS1 transcript is denoted at 12 (SAS). A
polypyrimidine tract extends from 91 to 109. Branch points for
trans-splicing of the FUS1 transcript
(B) are denoted at 112, 113, and 116.
|
|
 |
MATERIALS AND METHODS |
Culture Conditions--
T. cruzi line CL
epimastigotes were cultured in liver infusion tryptose medium
supplemented with 10% fetal calf serum and 0.1 mg/ml hemin (19) at
28 °C. Midlog phase cultures (5 × 106 to 2 × 107 cells/ml) were used in all experiments.
Electroporation, Stable Transformation, and Cloning of
Trypanosomes--
T. cruzi epimastigote electroporation was
performed as described by Hariharan et al. (20) with minor
modifications. In all cases, one or two rounds of antibiotic selection
were carried out with a recovery period in between. Clonal lines were
obtained by serial dilution in the absence of antibiotic selection, and tandem or single gene replacement lines were verified by Southern analysis (18). For TcCL:TR3, approximately 275 pmol of the gel-purified 2.7-kb1
MluI-EcoRV fragment from the pBS:CH6N3 plasmid
(described below and in the legend to Fig.
2A) was used during
electroporation of 3 × 108 epimastigotes. A
transformed hygromycin-resistant (Hygr) population was
selected by application of 500 µg/ml hygromycin B sulfate at 48 h post-electroporation. For the TcCL:FN3 line, the gel-purified 1.2-kb
AflII-EcoRV fragment from the plasmid pBS:FN3
(Fig. 2B) was used, and for the TcCL:CnFc and TcCL:SAM stable lines, the 2.5-kb MluI-EcoRV "CnFc"
fragment from pBS:CnFcII and pBS:SAM plasmids (described below and in
the legend to Fig. 2C) was used. Selection was carried out
by application of 250 µg/ml G418.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Diagrams of the pBS:CH6N3, pBS:FN3, and
pBS:CnFcII gene replacement constructs aligned with the targeted
2.65 locus sequences (not to scale).
A, the pBS:CH6N3 plasmid used to generate the TcCL:TR3
T. cruzi line. B, the pBS:FN3 plasmid used to
generate the T. cruzi TcCL:FN3 line used as a
positive/wild-type splicing FUS1/Neor
control. C, the pBS:CnFcII plasmid used to generate
TcCL:CnFc and TcCL:SAM stable lines. Intergenic sequences are labeled
within quotation marks. SAM6-F refers
to the F region carrying two point mutations as described under
"Materials and Methods" and Table I. T7 and T3 refer to the
location of the T3 and T7 primers in the vector, Bluescribe
(Stratagene). The thick black line
indicates polylinker sequences from the vector. Restriction sites are
given. Details of the plasmid construction are described under
"Materials and Methods."
|
|
Oligonucleotides--
All DNA oligonucleotides used in the
experiments are listed and described in Table I.
PCR Conditions--
Unless stated otherwise, polymerase chain
reaction amplifications (21) were carried out in a volume of 100 µl
containing 50 mM KCl, 10 mM Tris-Cl, pH 9.0, 1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM dNTPs, 2.5 units of Taq polymerase, 0.1 µg
of each primer, and either 10 ng of genomic DNA or 1 ng of plasmid DNA
as template. Standard amplification conditions were either 2 min at
94 °C, 1 min at 55 °C, and 2 min at 72 °C for 30 cycles or 2 min at 94 °C, 1 min at 50 °C, and 2 min at 70 °C for 30 cycles.
RNA Isolation and Northern Hybridizations--
Total cellular
RNA was isolated by the guanidinium/cesium chloride method of Sambrook
et al. (22) or by using TRIzol® (Life Technologies, Inc.)
according to the manufacturer's suggestions.
Blotting, hybridization, and washing conditions used in Northern
analyses were as described in Hariharan et al. (20), and Northern hybridizations were carried out on RNA that was
size-fractionated on 1.1% agarose gels containing 2.2 M
formaldehyde (22). Probes for the ubiquitin, calmodulin,
CUB, Neor, and CAT genes
used in Northern analysis were generated by PCR amplification as
described previously (18, 20, 23). The Hygr
probe was generated using Hyg1 and Hyg2 primers (Table I) to amplify
the protein coding sequence template. The tubulin probe was generated
using the Tub1 and Tub2 primers (Table I) to amplify the tubulin coding
sequence from the p164 plasmid (24).
32P Labeling of Oligonucleotide Primers--
Splint
labeling of the primers used during 5' extension and S1 nuclease
protection analyses was performed using a procedure based on the method
of Hausner et al. (25). Splint labeling was performed by PCR
amplification of a 2:1 ratio of biotin-conjugated CAT9 or Neo8 primer
to their complementary primers CAT10 or Neo7 in a 50-µl volume in the
PCR reaction conditions described above. Five cycles of 1 min at
95 °C, 1 min at 50 °C, and 1 min at 70 °C were carried out
followed by binding to avidin-agarose beads (Pierce) in PBS, 500 mM NaCl for 10 min at ambient temperature with periodic
vortexing. Binding was followed by one wash step with an equal volume
of PBS, 500 mM NaCl. To isolate the labeled primer, the
avidin-agarose-bound primers were resuspended in distilled H2O, boiled for 3 min, and pelleted. The labeled primer was
released into the supernatant.
The 5' terminus of the Tub10 oligonucleotide was phosphorylated using
T4 polynucleotide kinase (New England Biolabs) and
[ -32P]ATP.
Primer Extension Analysis--
Primer extensions were done
essentially as described by Sambrook et al. (22) with the
following modifications and conditions. Unless stated otherwise, 100 µg of total cellular RNA and approximately 33-50 ng of
splint-labeled primer were used. Primer annealing was carried out at
42 °C, and primer extensions using RNaseH , Moloney
murine leukemia virus reverse transcriptase (Superscript II, Life
Technologies, Inc.) were carried out at either 37 or 42 °C for
1 h. Quantitative primer extensions were performed by carrying out
simultaneous primer extensions of FUS1/CAT and
tubulin transcripts in a single reaction. During the quantitative 5'
extensions, 4 ng of 5' terminus-labeled Tub10 primer was used during
each reaction.
PhosphorImager Analysis--
The disintegrations/min of the
radioactive signals from the primer extension gels and Northern blots
were detected using a Molecular Dynamics Storm PhosphorImager, model
860. Analysis of the signals was carried out using Image QuaNT and
FragmeNT Analysis software (Molecular Dynamics).
S1 Nuclease Protection Analysis--
S1 nuclease protection
analyses were performed as described by Sambrook et al.
(22). The single-stranded DNA probe was generated by linear PCR
amplification of AflII-digested pBS:CH6N3 plasmid with
splint-labeled Neo8 primer (Fig. 4C). The 410-nt probe,
isolated from a 5% denaturing polyacrylamide gel, was annealed to 100 µg of total RNA overnight at 37 °C. S1 nuclease treatment was
performed at 37 °C for 1 h with 2 units of enzyme/µl of reaction.
Following digestion, all samples were precipitated, resuspended in 3 µl of formamide sample buffer, and separated on 5% polyacrylamide DNA sequencing gels.
Debranching of RNA--
HeLa cell S100 cytoplasmic extracts with
debranching activity were generously provided by Drs. Kenneth Watkins
and Nina Agabian (University of California, San Francisco) (7).
Debranching of total cellular RNA was carried out as described
previously except that 100 µg of RNA was treated for 2 h (7).
After debranching, the RNA was extracted with phenol and precipitated
prior to annealing with the labeled oligonucleotide and primer extension.
DNA Sequencing--
The DNA sequencing ladders included in the
S1 nuclease protection and primer extension analyses were Sequenase
version 2.0 (U.S. Biochemical Corp.)-catalyzed dideoxy sequences of
plasmid DNAs with primers chosen to match the 5'-end of the primer used in the S1 protection or 5' extension experiment. The template plasmid
was also matched to the experiment.
RNA Stability Analysis--
Midlog epimastigotes were treated
with actinomyocin D at a concentration of 10 µg/ml to inhibit
transcription. Trypanosomes were collected at the reported time points
(0, 30, 60, 90, 120, and 180 min). RNA was isolated with TRIzol® (Life
Technologies, Inc.) and analyzed by Northern blot for
FUS1/CAT mRNA. Blots were stripped by boiling
for 30 min in 1× SSC, 1.0% SDS and reprobed for tubulin.
pBS:CH6N3 and pBS:FN3 Constructions--
The plasmids used for
all experiments were constructed with the Bluescribe plasmid (pBS+/ )
from Stratagene, Inc., and sequenced to verify that unintentional
mutations were not introduced. Unless otherwise stated, all PCR
fragments and restriction sites were treated with T4 DNA polymerase to
generate blunt ends prior to ligation.
The plasmids pBS:CH6N3 and pBS:FN3 are shown in Fig. 2, A
and B, which shows the alignment of genomic T. cruzi sequences in the plasmid with portions of the wild-type
2.65 calmodulin-ubiquitin locus. The "C" and "300"
fragments and the Neor coding sequence were
generated by PCR amplification as described previously (18, 20). The
C region consists of the 525-bp sequence immediately upstream of
the initiation codon of CUB2.65, including the 3' splice
acceptor site (23). In pBS:CH6N3, the C fragment is fused to the
Hygr gene, generated by PCR amplification of the
protein coding sequence with Hyg1 and Hyg2 oligonucleotides. This
coding sequence was followed by the 362-bp "SAM6-F" region that
consists of the entire sequence between the coding sequences of the
CUB2.65 and the downstream FUS1 genes. The
"SAM6-F" fragment was generated by PCR amplification of a
wild-type "F" sequence with the oligonucleotides 5'F and SAM6,
which carried two point mutations (Table
I). The Neor gene
is fused to the F region and is flanked at its 3'-end with the 300 intergenic sequence, which separates FUS1 from
PUB12.5 (17, 18). The plasmid pBS:FN3 contains an F sequence
of 525 bp that extends into CUB2.65 coding sequence, which
was generated by PCR amplification with primers Ub-18 and Fuspro1 and
carries no point mutations. This fragment is ligated to the
Neor coding sequence, which is in turn followed
by the 300 fragment described above.
View this table:
[in this window]
[in a new window]
|
Table I
Sequences of DNA oligonucleotides that were used in the constructions
and/or analysesa
a All sequences are in 5' to 3'
orientation. Numbers indicate nucleotide positions with respect to the
indicated source. Primers that are the complement of coding strand
sequences are referred to as "reverse primers." Lowercase letters
indicate mutations or noncoding sequences, such as added restriction
sites, and are explained in the description of the oligonucleotide. A
reference or GenBankTM accession number is given for each
oligonucleotide where possible.
|
|
pBS:CnFc and pBS:CnFcSAM Constructions--
For these
experiments pBS:CnFc (18) was modified to eliminate the sup4
gene, flanked by XhoI restriction sites, by digestion with
XhoI and religation. The modified plasmid was named
pBS:CnFcII. Fig. 2C diagrams the pBS:CnFcII construct and
shows the alignment of genomic T. cruzi sequences in the
plasmid with the wild-type 2.65 calmodulin-ubiquitin locus.
Subsequent pBS:SAM constructs were derived from pBS:CnFcII and contain
the point mutations described in Table
II.
To generate the pBS:CnFcSAM plasmids, pBS:CnFcII was mutagenized by
site-directed mutagenesis using splice acceptor site mutation (SAM)
oligonucleotides: SAM1, SAM2, SAM3, SAM4, CATM1, and CATM2. In all of
the plasmids, the F region was sequenced to confirm that no spurious
mutations were introduced.
 |
RESULTS |
Deletion of a Native 3' Splice Acceptor Site Yields Multiple
Transcripts--
The first set of experiments were designed to better
understand trans-splicing of the FUS1 transcript
by eliminating its wild-type 3' splice acceptor site in the native
locus (18). Because CUB2.65 and FUS1 belong to
multicopy gene families, stable transformation was used to replace
these genes with Hyg and Neor,
respectively, while simultaneously introducing targeted point mutations
in the F intergenic region separating them (Fig. 1 and Ref. 18). Two
stable lines were generated (see "Materials and Methods"). TcCL:TR3
carried two mutations and both gene replacements. One mutation
eliminated the native AG dinucleotide 3' splice acceptor site by
creating an A to T substitution at position 14 relative to the
FUS1 translation initiation codon (Fig. 1). The second point
mutation in this line eliminated an alternative ATG translation initiation codon by creating a G to C substitution at position 24
(Fig. 1). TcCL:FN3 was the control stable line and carried the single
FUS1/Neor gene replacement and no mutations
within the F intergenic region.
TcCL:TR3 was one of several clonal lines isolated from a
hygromycin-resistant population. Selection for expression of the FUS1/Neor gene replacement was never imposed so
that mutations that may have blocked expression of the
Neor gene could be represented in the original
transformed parasite population. TcCL:TR3, like all tandem replacement
lines analyzed, was found to lack neomycin phosphotransferase II
activity despite the presence of the FUS1/Neor
gene replacement (data not shown). This suggested that if the FUS1/Neor gene was transcribed, cryptic 3'
splice acceptor sites within the F region were not used, since this
would have led to neomycin phosphotransferase II production. By
comparison, the clonal line TcCL:FN3, which also carried the
FUS1/Neor gene replacement but retained the
native 3' splice acceptor site, expressed neomycin phosphotransferase
II activity that was over 1 × 105-fold above
background levels (data not shown). Taken together, the lack of
neomycin phosphotransferase II activity and verification of the
successful gene replacement indicated that although TcCL:TR3 carried
the FUS1/Neor gene replacement, the protein
product was not expressed, presumably because eliminating the 3' splice
acceptor site blocked maturation of the
FUS1/Neor mRNA. To determine how completely
FUS1/Neor gene expression was blocked and
whether spontaneous mutations restoring expression could be isolated,
the TcCL:TR3 line was subjected to G418 selection (data not shown).
Despite repeated attempts, G418-resistant parasites were never
isolated, which indicated that the introduced mutation was stable.
Although the analyses indicated that the
FUS1/Neor gene product of TcCL:TR3 was not
expressed, they did not address whether the gene was transcribed and,
if so, how the transcript was processed. To address the first of these
questions, the Northern blot analysis shown in Fig.
3 was carried out. Five replicate blots
of total RNA isolated from either nontransformed T. cruzi or
TcCL:TR3 parasites were hybridized with calmodulin, CUB,
ubiquitin, Hyg, and Neor coding
sequence probes (see "Materials and Methods"). As expected, TcCL:TR3 parasites expressed the calmodulin and ubiquitin genes but
lacked the 1.1-kb CUB2.65 mRNA (Fig. 3, panel
CUB, lane 2). TcCL:TR3 also expressed the
CUB2.65/Hygr mRNA (Fig. 3, panel
Hyg, lane 2). The Neo probe recognized two RNAs in
TcCL:TR3 of approximately 1.2 and 1.4 kb (Fig. 3, panel Neo,
lane 2), raising the possibility that these RNAs were either alternatively spliced nontranslatable products, nonspliced RNA processing intermediates, or both. In addition, the extended exposure necessary to detect the FUS1/Neor
transcripts in TcCL:TR3, suggested the RNAs were expressed at low
levels relative to the native FUS1 mRNA. In contrast,
the expected single transcript was detected by the Neo probe in
TcCL:FN3 (data not shown; see Ref. 18).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 3.
The TcCL:TR3 mutant produces two
Neor transcripts. Northern blot
analysis of calmodulin-ubiquitin loci and marker gene transcripts in
wild-type T. cruzi and stable TcCL:TR3 transformants. Each
lane contains 10 µg of total cellular RNA isolated from
either wild-type (WT) nontransformed T. cruzi
(lanes 1) or line TcCL:TR3 (lanes 2).
The probes are as described under "Materials and Methods."
Approximate transcript sizes are in kb. The Cal, CUB, and Ub probed
membranes were exposed for 30 h with two intensifying screens. The
Hyg and Neo probed membranes were exposed for 16 days with one
intensifying screen on preflashed film.
|
|
Altered Processing of the FUS1/Neor Transcripts of
TcCL:TR3--
To further characterize the two
FUS1/Neor transcripts observed in TcCL:TR3,
primer extension and S1 nuclease protection analyses were carried out
(see "Materials and Methods"). These experiments demonstrated that
a subset of the FUS1/Neor transcripts were
trans-spliced within the FUS1/Neor
protein coding sequence, and the remainder were nonspliced RNAs with
defined 5' termini.
Primer extension analyses were carried out using an oligonucleotide
complementary to the Neor coding strand to prime
reverse transcription of total RNA isolated from TcCL:TR3, wild-type,
or TcCL:FN3 parasites (Fig.
4A). The RNA from TcCL:FN3 and
wild-type nontransformed parasites were included as positive and
negative controls, respectively. No reverse transcription products were
generated from wild-type RNA as expected (Fig. 4A,
lane 3). The TcCL:FN3 primer extension product (Fig. 4A, lane 2) indicated the
FUS1/Neor transcript was
trans-spliced at position 12, the previously identified
native 3' splice acceptor site for FUS1 (Fig. 1 and Ref.
18). The 47-nt reverse transcription product included 12 nt of the
FUS1/Neor 5'-untranslated region and 35 nt of
the 39-nt spliced leader sequence. As previously noted, modification of
the 4,5'-terminal bases of the spliced leader blocked further reverse
transcription (3). It can also be seen that in TcCL:FN3 splicing at
position 12 was quantitative with no splicing detected at the next AG dinucleotide downstream.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 4.
Mutant line TcCL:TR3 produces both spliced
and nonspliced Neor transcripts.
Primer extension and S1 nuclease protection analysis of TcCL:TR3 and
TcCL:FN3 Neor transcript 5'-ends is shown.
A and B are autoradiographs of primer extension
and S1 nuclease analysis of total RNA, respectively. The
hash-marked bands and numbers
indicated are described under "Results." Sequencing ladders
are pBS:CH6N3 primed with the Neo8 oligonucleotide (Table I), thus
allowing direct determination of the size and position of fragments.
A, primer extension analysis with splint-labeled Neo8
oligonucleotide (Table I). Lane 1, TcCL:TR3;
lane 2, TcCL:FN3; lane 3,
wild type (WT). Film exposure was for 11 days at ambient
temperature. B, S1 nuclease analysis. Lane
1, TcCL:TR3; lane 2, TcCL:FN3;
lane 3, wild type (WT);
lane P, 1:100 dilution of probe. Film exposure
was for 2.5 days with one intensifying screen. C, diagram of
the S1 nuclease protection probe generation. D, diagram of
the effect of the branched intermediates on primer extension
(PE) and S1 nuclease protection (S1)
analysis.
|
|
The results of the 5' extension analysis from TcCL:TR3 were more
complex. Multiple extension products were detected including the
product expected from a template RNA, which was
trans-spliced at position +14, the first AG dinucleotide
downstream of the polypyrimidine tract in TcCL:TR3 (see +14
in Fig. 4A, lane 1). A comparison of the
intensities of the TcCL:FN3 ( 12) primer extension product and the
TcCL:TR3 (+14) product suggested that splicing at the +14 site may be
less efficient than splicing at the native site in TcCL:FN3. Three
longer products at positions 112, 113, and 116 were also
reproducibly observed in TcCL:TR3 (Fig. 4A, lane 1). These products were unlikely to represent additional
trans-spliced FUS1/Neor mRNAs for
two reasons. First, this region contains no AG dinucleotides at the
positions where they would be expected if these were
trans-spliced RNAs, and second, trans-splicing at
these sites would lead to expression of neomycin phosphotransferase II.
Closer examination revealed that these three products mapped to three A
nucleotides immediately upstream of an uninterrupted polypyrimidine
tract (Fig. 1), suggesting that they represented reverse transcription products in which extension was blocked by a Y-branched structure. The
other products of intermediate length seen in TcCL:TR3 may have been
due to secondary structures predicted to form within this region of the
F sequence (data not shown; see Ref. 27), which blocked reverse
transcriptase. At this point, they have not been investigated further.
To confirm the identity of the 3' splice acceptor sites and support the
identification of potential branch points within the F intergenic
region, S1 nuclease protection was carried out on the same RNA samples
(see "Materials and Methods" and Fig. 4B). Since the
single-stranded end-labeled DNA probe lacked sequence complementary to
the spliced leader sequence (see Fig. 4C), protection by
trans-spliced mRNAs would generate products 35 nucleotides shorter than the corresponding 5' extension products. In
TcCL:FN3, a single protection product mapping to the 12 native 3'
splice acceptor site was obtained (Fig. 4B, lane
2), confirming the results of the primer extension analysis. In
contrast, multiple products were generated from the TcCL:TR3 sample
(Fig. 4B, lane 1). The shortest protection
fragment represented FUS1/Neor mRNA spliced
at +14 and corresponded to the product mapped by 5' extension. The
protected fragments at 160/ 162 did not correspond to any previously
observed primer extension products (Fig. 4A, lane
1) and these products were substantially longer than any of the 5'
extension products. As shown below, the templates for these protection
products were Y-branched FUS1/Neor RNAs, which
carried a defined 5' terminus. Fig. 4D illustrates the
probable sources of the products of S1 nuclease protection and primer
extension of FUS1/Neor RNA of TcCL:TR3.
Identification of Branched FUS1/Neor RNAs in
TcCL:TR3--
To confirm the identification of the Y-branched
intermediates, the TcCL:TR3 RNA sample was treated with a HeLa cell
debranching extract prior to 5' extension analysis (see "Materials
and Methods" and Ref. 7). If a Y-branched structure was causing
premature termination of reverse transcriptase, then eliminating the
branch structure would result in 5' extension and S1 nuclease
protection products of equal length.
TcCL:TR3 RNA was subjected to three treatments. One sample was analyzed
by 5' extension (Fig. 5A,
lane PE), a second sample was debranched prior to 5'
extension analysis (Fig. 5A, lane D), and a third
sample was subjected to S1 nuclease protection (Fig. 5A,
lane S1). The 5' extension products corresponding to the
putative branch points were evident in the untreated RNA sample (Fig.
5A, lane PE) but were not seen in the debranched
RNA sample (Fig. 5A, lane D). Rather, a new
product was generated, which corresponded in length to the longer S1
nuclease protection product (Fig. 5A, lane
S1). As expected, the debranching extract had no effect on the mature trans-spliced mRNA as indicated by the +14
extension product in both samples (Fig. 5A, lanes
PE and D). The same treatments and analyses performed
on TcCL:FN3 RNA showed that the debranching extract had no effect on
the trans-spliced TcCL:FN3
FUS1/Neor mRNA (Fig.
5B). Thus, these results confirmed that the template RNAs
carried Y-branched structures with a defined 5' terminus, which mapped
to position 160/ 162.

View larger version (94K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of debranched TcCL:TR3 total RNA
shows that Y-branched Neor transcript
splicing intermediates are accumulated. A, analysis of
TcCL:TR3 RNA Neor transcripts. B,
analysis of TcCL:FN3 Neor transcripts. Products
of interest are labeled with brackets and hash-marked
numbers. For clarity, the numbers are also classified with a
technique abbreviation in parentheses: PE for primer
extension and S1 for S1 nuclease protection. Lane
PE, splint-labeled Neo8 primer (Table I) extension;
lane D, splint-labeled Neo8 primer extension of
debranched total RNA; lane S1, S1 nuclease
protection; lane P, S1 nuclease protection probe
control; lane 1/100, 1:100 dilution of S1
nuclease protection probe. B marks the branch sites at
112, 113, and 116 in A. Numbers are
described under "Results." Sequencing ladders are pBS:CH6N3
primed with the Neo8 oligonucleotide, thus allowing direct
determination of the size and position of fragments. Autoradiograph
exposures were for 2.5 days with one intensifying screen for
A and 2 days at ambient temperature for B.
|
|
Generation of SAM Stable Lines--
The analysis of the
FUS1/Neor transcripts of TcCL:TR3 supported the
scanning hypothesis for the selection of the 3' splice acceptor site
during trans-splicing. This hypothesis suggests that during
the second step of splicing, the spliceosome scans the RNA downstream
of the branch point in a 5'-3' direction and splices at the first AG
dinucleotide it encounters (10, 28). To further test this hypothesis,
additional mutant stable lines were generated, which carried mutations
in the F region such that the first AG dinucleotide in each line
occurred at a different position downstream of the branch points (Table
II and Fig. 6). For these experiments,
the inserts from the plasmids pBS:CnFcII and pBS:SAM(s) (see
"Materials and Methods" and Fig. 2C) were used to
generate the stable transformants carrying
CUB2.65/Neor and FUS1/CAT
gene replacements. pBS:CnFcII carried the native F intergenic region
(Fig. 1). pBS:SAM plasmids each carried point mutations in the F
intergenic and CAT coding sequences, which placed the
consensus AG dinucleotide at various positions (Table II and Fig. 6).
For pBS:SAM 59, 35, and 23, one point mutation was introduced into
the F sequence that placed the first consensus splice acceptor site at
59, 35, and 23, respectively, relative to the first nucleotide of
FUS1/CAT coding sequence. The wild-type site at 12 was
retained in these constructs. For pBS:SAM+7, the wild-type splice
acceptor site was eliminated by deleting the A residue at 14, which
left the AG dinucleotide at position +7 within the CAT
coding sequence as the first potential 3' splice acceptor site. For
pBS:SAM+10 and +14, the wild-type splice acceptor site was eliminated,
and point mutations were introduced within the CAT sequence
such that an AG dinucleotide occurred at a position that would direct
splicing at +10 or +14, respectively.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 6.
Schematic representations of the F region in
TcCL:CnFc and TcCL:SAM stable lines. The partial F intergenic and
CAT coding regions are represented diagrammatically by a
line. The relative positions of the AG dinucleotides are
indicated, and point mutations are given by lowercase in
each stable line (refer to Table II). The polypyrimidine tract ( 109
to 91) is represented by a hatched rectangle,
and the branch points hatch marks are marked by B. ,
deletion of one nucleotide at the native 3' splice site. The
translation initiation codon is marked by a hatch
mark at +1. The first AG dinucleotide downstream of the
branch point is denoted by an underline.
|
|
TcCL:SAM Stable Lines Support Scanning Model for the Selection of
the 3' Splice Acceptor Site--
Northern blot analysis indicated that
each TcCL:SAM line produced FUS1/CAT mRNAs of
approximately 1.0 kb as expected (Fig. 7A) (18), although the
detected level of FUS1/CAT mRNA varied from line to
line. TcCL:CnFc, which carried the native F region, had the highest
level of FUS1/CAT mRNA (Fig. 7A, lane
2), suggesting that the mutations carried by the TcCL:SAM lines
had variably adverse effects. TcCL:SAM 59, 35, and +7 (Fig.
7A, lanes 3, 4, and 6)
exhibited the most dramatic decreases in FUS1/CAT mRNA levels, since in these lines transcripts could only be detected with
extended exposure of the autoradiograph (Fig. 7A). Overall, the Northern blot analysis was consistent with the notion that the
mutations introduced in the TcCL:SAM lines had adversely affected maturation of the FUS1/CAT transcripts.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 7.
TcCL:SAM stable lines produce reduced levels
of FUS1/CAT mRNA spliced at the first AG
dinucleotide downstream of the branch point. A,
Northern analysis of TcCL:CnFc and TcCL:SAM stable transformants. Each
lane contains 10 µg of total cellular RNA isolated from
the following: nontransformed wild-type T. cruzi
(lane 1); TcCL:CnFc (lane
2); TcCL:SAM 59 (lane 3);
TcCL:SAM 35 (lane 4); TcCL:SAM 23
(lane 5); TcCL:SAM+7 (lane
6); TcCL:SAM+10 (lane 7); TcCL:SAM+14
(lane 8). Approximate size of the
FUS1/CAT transcript is shown to the left in kb.
The Northern blot was hybridized with a probe that detected
CAT mRNA as described under "Materials and Methods."
The blot was exposed with one intensifying screen for 14 days at
70 °C. B, quantitative primer extension of TcCL:CnFc
and TcCL:SAM stable transformants. Autoradiograph showing the results
of the primer extension analysis. One hundred µg of total cellular
RNA from TcCL:CnFc and each of the TcCL:SAM stable lines was analyzed
using primer extension analysis (see "Materials and Methods").
Splint-labeled CAT10 primer (Table I) was used to analyze the position
of the splice acceptor site of the FUS1/CAT message in each
line, and 5' terminus-labeled Tub10 primer (Table I) was used as an
internal control to allow the amount of FUS1/CAT message to
be compared between lines. Primer extensions from RNA isolated from
T. cruzi lines appear in the following lanes: nontransformed
wild-type T. cruzi (lane 1); TcCL:CnFc
(lane 2), TcCL:SAM 59 (lane
3); TcCL:SAM 35 (lane 4);
TcCL:SAM 23 (lane 5); TcCL:SAM+10
(lane 6); TcCL:SAM+14 (lane
7); TcCL:SAM+7 (lane 8). The sequence
ladder was generated with CAT10 primer and pBS:CnFcII.
Numbers on the left indicate the position of the
splice acceptor site relative to the translation start site of
FUS1/CAT. The 76-nt tubulin extension product is denoted.
The autoradiograph was exposed for 2 days at ambient temperature.
|
|
Quantitative primer extension analyses were carried out to assess how
the SAM mutations affected trans-splicing of the
FUS1/CAT transcripts. The position of the splice acceptor
site in each line was determined using an oligonucleotide that was
complementary to the CAT coding sequence to prime reverse
transcription (see Fig. 7B and "Materials and Methods").
The quantity of FUS1/CAT product in each parasite line was
normalized to the  tubulin extension product so that the amounts of
spliced FUS1/CAT mRNA could be compared between lines
(Table III).
The results of the primer extensions are shown in Fig. 7B
and Table III, which includes a description of the 3' splice acceptor site used and the relative quantity of FUS1/CAT mRNA for
each line. In all of the TcCL:SAM lines, the levels of
trans-spliced FUS1/CAT mRNA were reduced to
8-28% of that detected in TcCL:CnFc (Table III). For example, in
TcCL:SAM+14, the intensity of the CAT primer extension
product detected at position +14 is approximately 28% of that detected
in TcCL:CnFc (Fig. 7B, lanes 2 and 7).
In TcCL:SAM 35, the intensity of the CAT primer extension
product was only 8% of that detected in TcCL:CnFc (Fig. 7B,
lanes 2 and 4).
Supporting the scanning model for 3' splice acceptor site selection,
splicing in TcCL:CnFc occurred specifically at the wild-type site at
12 (Fig. 7B, lane 2) as expected. The results
from the TcCL:SAM stable lines further support this model, since
splicing in each stable line occurred predominantly at the first AG
dinucleotide downstream of the branch points and polypyrimidine tract.
Two of the stable lines, TcCL:SAM 59 and 23 (Fig. 7B,
lanes 3 and 5), exhibited a small degree of
splicing at the wild-type site. In these two lines, both the amount of
spliced FUS1/CAT mRNA and the precision of splicing were
affected by the mutations in the F region. In contrast, no splicing at
the wild-type site could be detected in TcCL:SAM 35, although the
quantity of FUS1/CAT mRNA was decreased by 5-fold,
indicating that although precision was maintained, efficiency was
decreased (Fig. 7B, lane 4, and Table III). For
TcCL:SAM+7, +10, and +14 (Fig. 7B, lanes 6-8), splicing occurred within the CAT coding sequence at
positions +7, +10, and +14, respectively. Minor primer extension
products were also detected near the position of the wild-type splice
acceptor site despite the absence of an AG at 12 in these clones.
Preliminary experiments indicate that these products represent
FUS1/CAT transcripts that were spliced at non-AG
dinucleotides (data not shown). Longer exposure of the autoradiograph
in Fig. 7B also revealed primer extension products in
TcCL:SAM+7, +10, and +14 that mapped to the three A residues at
positions 112, 113, and 116, which have been previously
identified as branch points for the FUS1 transcript.
SAM Mutations Decrease the Efficiency of trans-Splicing of the
FUS1/Neor Transcripts--
The diminished levels of
FUS1/CAT transcripts detected in the TcCL:SAM lines could
have been the result of one or more mechanisms including alterations in
transcription, RNA processing, or mRNA stability. Since
transcription in trypanosomes is polycistronic (4, 29) and constitutive
transcription across the 2.65 calmodulin-ubiquitin locus has
been demonstrated (30), it is unlikely that the point mutations
introduced in the TcCL:SAM stable lines affected transcription of the
FUS1/CAT gene. To distinguish between the other two
possibilities, the stability of the FUS1/CAT mRNA
expressed in three different lines was assessed (see "Materials and
Methods"). TcCL:CnFc served as the control, since splicing occurs
exclusively at the wild-type site in this line. TcCL:SAM 23 and +7
were analyzed, because the point mutations in these clones had
respectively smaller and larger effects on expression from the
FUS1 locus when compared with expression in the other
TcCL:SAM lines (Table III).
Fig. 8 shows Northern blots that are
representative of the results obtained in the RNA stability analysis.
The same Northern blots stripped and probed for tubulin transcripts are
included as a control, since tubulin mRNA has a half-life that is
significantly longer than that of FUS1/CAT mRNA (data
not shown). Analysis of the RNA isolated at various time points after
inhibition of transcription revealed that the half-life of
FUS1/CAT mRNA for all of the clones analyzed was
approximately the same (Table IV).
Importantly, the point mutations introduced in these TcCL:SAM lines had
no effect on the stability of the FUS1/CAT transcripts.
Hence, coupling these results with the results of the quantitative
primer extension analysis suggests that decreased efficiency of
splicing in the F region is responsible for reduced levels of
FUS1/CAT transcripts in the TcCL:SAM lines.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 8.
Stability of FUS1/CAT
mRNA is unaltered in TcCL:SAM stable transformants. The
lines TcCL:CnFc, TcCL:SAM 23, and TcCL:SAM+7 were analyzed. Total RNA
was isolated at various times after inhibition of transcription (0, 30, 60, 90, 120, and 180 min) and analyzed by Northern blot (10 µg/lane).
Each blot was hybridized first with the CAT probe and then stripped and
rehybridized with the tubulin probe (see "Materials and Methods").
The autoradiographs for FUS1/CAT Northern blots were exposed
for the following lengths of time: TcCL:CnFc, 2 days with one
intensifying screen at 70 °C; TcCL:SAM 23, 6 days with two
intensifying screens at 70 °C; TcCL:SAM+7, 10 days with two
intensifying screens at 70 °C. The autoradiographs for tubulin
Northern blots were exposed for 1 day at ambient temperature.
|
|
 |
DISCUSSION |
trans-Splicing is a process in trypanosomes that is
required for the maturation of mRNA. To understand this process, it
is important to identify the cis-acting sequences involved
and, further, to understand the interplay between these sequences that
leads to productive trans-splicing. The AG dinucleotide at
the 3' splice acceptor site and its associated upstream polypyrimidine
tract(s) are the most prominent and highly conserved
cis-acting sequences of the trypanosomal pre-mRNA (9,
14). This report centered on studying the effects of subtle point
mutations that deleted the native AG 3' splice acceptor site and/or
introduced new AG dinucleotides in the region surrounding the native 3'
splice site of the FUS1 transcript.
In TcCL:TR3, the elimination of the native 3' splice acceptor site
within the F region led to splicing at the next AG dinucleotide downstream and the accumulation of Y-branched intermediates. These intermediates facilitated the mapping of the first bona fide
branch points in T. cruzi, only the second identified in
trypanosomatids (16). Branching on the FUS1/Neor
pre-mRNA occurred at the three A residues directly upstream of the
only polypyrimidine tract. Furthermore, analysis of TcCL:TR3 also
provides evidence for the scanning model for 3' splice site selection
(10, 28) during trans-splicing as illustrated through two
observations. The first is that the native 3' splice acceptor site for
the FUS1 transcript occurs at the first AG dinucleotide downstream of the branch points and polypyrimidine tract (18). Second,
in the absence of the native 3' splice acceptor site in TcCL:TR3,
splicing occurred at the next AG dinucleotide downstream at +14.
The scanning model for 3' splice site selection suggests that the
pre-mRNA is scanned by some component(s) of the spliceosome and
splicing occurs at the first AG dinucleotide downstream of the branch
point (28, 32). This model has been supported in cis-splicing by carefully designed experiments done in
vitro and in vivo using yeast and mammalian transcripts
(33-36). The experiments demonstrated that under most circumstances,
when the position of the AG was altered by mutation, splicing occurred
at the downstream AG dinucleotide closest to the branch point. Analyses
of mapped native splice sites from cis-spliced RNAs also
suggest that splicing occurs at the first AG downstream of the
predicted branch point (10). Furthermore, bimolecular splicing
experiments in which the 5' splice site, branch point, and
polypyrimidine tract are located on an RNA separate from that RNA
carrying the 3' splice site suggest that these RNAs can be spliced
together (37). These experiments demonstrate that a 5' to 3' scanning
mechanism may be operational, since splicing occurs at the AG
dinucleotide closest to the 5'-end of the target RNA.
The analysis of the TcCL:SAM stable lines provides the first set of
experiments designed specifically to address the scanning hypothesis
for 3' splice acceptor site selection (10, 28) during
trans-splicing. These lines each carried a unique set of mutations that placed the first AG dinucleotide at various positions downstream of the branch point. The data observed from each of the
lines supported the scanning model, since splicing occurred predominantly at the first AG dinucleotide downstream of the branch points. These analyses provide experimental support for the
evolutionary conservation of a scanning mechanism used during RNA
splicing in eukaryotic organisms. Additional support for the scanning
model during trans-splicing comes from Patzelt et
al., who identified the branch points of T. brucei -
and -tubulin transcripts in which splicing also occurred at the
first AG dinucleotide downstream (16). In trypanosomatids, it has been
difficult to assess whether other native 3' splice sites occur at the
first AG downstream of the branch site, because no consensus sequence
for branching has been determined, and other branch points have not
been experimentally mapped in trypanosomatids.
In addition to these findings, the analysis of the SAM mutations
suggests that splicing at the first AG dinucleotide downstream from the
branch point may not always be precise. For example in TcCL:SAM 59 and
23, although the predominant splicing event occurred at the first AG
dinucleotide downstream of the branch point, a small amount of splicing
was also detected at the intact wild-type splice site at 12. This
contrasts with the observations from TcCL:CnFc and TcCL:SAM 35 in
which splicing at one site is quantitative. Perhaps quantitative
splicing at these sites was not observed because the positions of these
AG dinucleotides along the primary transcript or nucleotide context
surrounding the new sites in TcCL:SAM 59 and 23 are not optimal.
cis-Splicing in yeast and metazoans can be affected by
distance between the branch point and the splice acceptor site, quality
and length of the polypyrimidine tract, context of the splice site, or
any combination of these factors (33, 35, 38, 39, 41, 42). Another
possibility for the low level of promiscuous splicing observed in the
TcCL:SAM stable lines is that the secondary structure of the precursor RNA molecule may affect the availability of a consensus site to be
recognized by the splicing machinery (43, 44). A more detailed analysis
will have to be undertaken to better understand how other cis-acting factors affect splice acceptor site selection in
trans-splicing and to better understand how the combination
of different cis-acting factors influence
trans-splicing.
Presently it is unclear why splicing is directed to the first AG
downstream of the branch point of the pre-mRNA. Recent
cross-linking studies using extracts from HeLa cell nuclei and
Caenorhabditis elegans suggest that the small subunit of the
U2 auxiliary factor, U2AF35, directly contacts and binds to
the 3' splice acceptor site and exon sequences located immediately
downstream in a sequence-dependent manner (45, 46). Coupled
with evidence that the large subunit, U2AF65, is important
for recognizing and binding to the polypyrimidine tract and branch
point (47, 48), splicing at the first AG downstream of the branch point
may be a consequence of these combined interactions. A similar model
could be proposed in trans-splicing, since
U2AF35 was demonstrated to cross-link to the 3' splice site
of trans-splicing pre-mRNAs in HeLa nuclei extracts
(46), and homologues of both U2AF subunits have been identified through
sequence analysis in the trypanosomatid Leishmania major
(GenBankTM accession numbers AC005836 and AC005893).
Additionally, there are a number of other factors that may also
influence 3' splice site selection. For example, Slu7p is a
spliceosomal component that was originally identified in yeast from a
screen of mutants that were synthetically lethal with mutations of U5
snRNA (49). In vitro experiments have demonstrated that the
absence of this splicing factor is coupled with a loss of fidelity of
splicing at the 3' splice site (50). The importance of its involvement
in splicing becomes more evident when the 3' splice site is distal to
the branch point (51). The characterization of U5 small nuclear
ribonucleoprotein-associated proteins suggests that they also may
determine 3' splice site choice. Prp8p is one of the most highly
conserved of these proteins (52) that binds to both the 5' and 3'
splice sites (53-55). Recent studies show that mutants of Prp8
suppress mutations at both splice sites, thus suggesting that it plays
a role during 3' splice site selection (53, 56). In addition, it is
associated with other U5 small nuclear ribonucleoprotein proteins that
carry RNA helicase domains, RNA unwindase activity, or homology to the
translational elongation factor, EF2 (see Ref. 57 and references
therein). Together, the U5 small nuclear ribonucleoprotein factors may
work in a concerted fashion to effect a scanning mechanism and select
and position the 3' splice site during catalysis. Some of these
interactions may be conserved during trans-splicing, since
studies indicate that a homologue of Prp8p identified in T. brucei associates with SLA2, the trypanosome U5 snRNA homologue
(58). More studies are necessary to determine which
trans-acting factors and what mechanism(s) dictates
selection of the 3' splice site.
The need for a mechanism operating during trans-splicing
that would reduce the likelihood of disruption of an open reading frame
is illustrated by results from TcCL:SAM+7, +10, and +14 and TcCL:TR3,
lines that in the absence of the native 3' splice site spliced at the
first AG dinucleotide within the protein coding sequence. As a result,
translation of the truncated mRNA would be effectively blocked. A
scanning mechanism (59) or the interaction of the U2AF could furnish
such a device, since they direct splicing to a site near a branch
point, thus decreasing the possibility of splicing within an open
reading frame.
Analysis of both the TcCL:SAM and TcCL:TR3 lines suggest in addition to
determining the splice site, the position of the AG may effect the
efficiency of trans-splicing. The reduced efficiency of
splicing observed in the TcCL:SAM lines and the appearance of
stabilized Y-branched intermediates in TcCL:TR3 suggest that the
position of the 3' splice acceptor site could directly affect the level
of expression of various proteins. Furthermore, this analysis,
particularly the results of TcCL:SAM 35, suggests that splicing can be
inefficient but remain precise. Inefficient but precise
trans-splicing may be one means for reducing the amount of
translatable mRNA. These results, taken together, support the theory that cis-acting factors influence how efficiently
transcripts are trans-spliced and may explain how mature
transcripts originating from one polycistronic unit are present at
various levels (26, 31, 40).
 |
ACKNOWLEDGEMENT |
We acknowledge the assistance of Lee Danley in
the preparation of many of the illustrations presented in this work.
 |
FOOTNOTES |
*
This work was supported by United States Public Health
Service Grant AI26578 (to J. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) L01583.
Present address: Infectious Disease Research Inst., 1124 Columbia
St., Suite 600, Seattle, WA 98104.
§
Present address: Dept. of Pathology, College of Veterinary Medicine
and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.
¶
To whom correspondence should be addressed: Dept. of
Microbiology and Immunology, University of Tennessee, Memphis, 858 Madison Ave., Memphis, TN 38163. Tel.: 206-754-5714; Fax: 206-754-5715; jswindle{at}IDRI.org.
Published, JBC Papers in Press, August 10, 2000, DOI 10.1074/jbc.M002424200
 |
ABBREVIATIONS |
The abbreviations used are:
kb, kilobase(s);
bp, base pair(s);
PCR, polymerase chain reaction;
PBS, phosphate-buffered saline;
nt, nucleotide(s);
SAM, splice acceptor
site mutation.
 |
REFERENCES |
| 1.
|
Agabian, N.
(1990)
Cell
61,
1157-1160
|
| 2.
|
Nilsen, T. W.
(1993)
Annu. Rev. Microbiol.
47,
413-440
|
| 3.
|
Perry, K. L.,
Watkins, K. P.,
and Agabian, N.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
8190-8194
|
| 4.
|
Johnson, P. J.,
Kooter, J. M.,
and Borst, P.
(1987)
Cell
51,
273-281
|
| 5.
|
Ruskin, B.,
Krainer, A. R.,
Maniatis, T.,
and Green, M. R.
(1984)
Cell
38,
317-331
|
| 6.
|
Padgett, R. A.,
Konarska, M. M.,
Grabowski, P. J.,
Hardy, S. F.,
and Sharp, P. A.
(1984)
Science
225,
898-903
|
| 7.
|
Murphy, W. J.,
Watkins, K. P.,
and Agabian, N.
(1986)
Cell
47,
517-525
|
| 8.
|
Sutton, R. E.,
and Boothroyd, J. C.
(1986)
Cell
47,
527-535
|
| 9.
|
Perry, K.,
and Agabian, N.
(1991)
Experientia
47,
118-128
|
| 10.
|
Mount, S. M.
(1982)
Nucleic Acids Res.
10,
459-472
|
| 11.
|
De Lange, T.,
Berkvens, T. M.,
Veerman, H. J.,
Frasch, A. C.,
Barry, J. D.,
and Borst, P.
(1984)
Nucleic Acids Res.
12,
4431-4443
|
| 12.
|
Matthews, K. R.,
Tschudi, C.,
and Ullu, E.
(1994)
Genes Dev.
8,
491-501
|
| 13.
|
Le Bowitz, J. H.,
Smith, H. Q.,
Rusche, L.,
and Beverley, S. M.
(1993)
Genes Dev.
7,
996-1007
|
| 14.
|
Huang, J.,
and Van, d. P., L. H.
(1991)
EMBO J.
10,
3877-3885
|
| 15.
|
Hug, H.,
Hotz, H.-R.,
Hartmann, C.,
and Clayton, C.
(1994)
Mol. Cell. Biol.
14,
7428-7435
|
| 16.
|
Patzelt, E.,
Perry, K. L.,
and Agabian, N.
(1989)
Mol. Cell. Biol.
9,
4291-4297
|
| 17.
|
Swindle, J.,
Ajioka, J.,
Eisen, H.,
Sanwai, B.,
Jacquemot, C.,
Browder, Z.,
and Buck, G.
(1988)
EMBO J.
7,
1121-1127
|
| 18.
|
Gillespie, R. D.,
Ajioka, J.,
and Swindle, J.
(1993)
Mol. Biochem. Parasitol.
60,
281-292
|
| 19.
|
Camargo, E. P.
(1964)
Rev. Inst. Med. Trop. Sao Paulo
6,
93-100
|
| 20.
|
Hariharan, S.,
Ajioka, J.,
and Swindle, J.
(1993)
Mol. Biochem. Parasitol.
57,
15-30
|
| 21.
|
Mullis, K. B.,
and Faloona, F.
(1987)
Methods Enzymol.
155,
335-350
|
| 22.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 23.
|
Ajioka, J.,
and Swindle, J.
(1993)
Mol. Biochem. Parasitol.
57,
127-136
|
| 24.
|
Thomashow, L. S.,
Milhuasen, M.,
Rutter, W. J.,
and Agabian, N.
(1983)
Cell
32,
35-43
|
| 25.
|
Hausner, T.-P.,
Giglio, L. M.,
and Weiner, A. M.
(1990)
Genes Dev.
4,
2146-2156
|
| 26.
|
Muhich, M. L.,
and Boothroyd, J. C.
(1988)
Mol. Cell. Biol.
8,
3837-3846
|
| 27.
|
Zuker, M.
(1989)
Science
244,
48-52
|
| 28.
|
Lang, K. M.,
and Spritz, R. A.
(1983)
Science
220,
1351-1355
|
| 29.
|
Kooter, J. M.,
van der Spek, H. J.,
Wagter, R.,
d'Oliveira, C. E.,
van der Hoeven, F.,
Johnson, P. J.,
and Borst, P.
(1987)
Cell
51,
261-272
|
| 30.
|
Jaishankar, S.
(1996)
Microbiology and Immunology
, University of Tennessee, Memphis
|
| 31.
|
Gonzalez, A.,
Lerner, T. J.,
Huecas, M.,
Sosa-Pineda, B.,
Noqueira, N.,
and Lizardi, P. M.
(1985)
Nucleic Acids Res.
13,
5789-5804
|
| 32.
|
Spritz, R. A.,
and Lang, K. M.
(1983)
Prog. Clin. Biol. Res.
134,
77-90
|
| 33.
|
Smith, C. W. J.,
Porro, E. B.,
Patton, J. G.,
and Nadal-Ginard, B.
(1989)
Nature
342,
243-247
|
| 34.
|
Smith, C. W.,
Chu, T. T.,
and Nadal-Ginard, B.
(1993)
Mol. Cell. Biol.
13,
4939-4952
|
| 35.
|
Reed, R.
(1989)
Genes Dev.
3,
2113-2123
|
| 36.
|
Luukkonen, B. G.,
and Seraphin, B.
(1997)
EMBO J.
16,
779-792
|
| 37.
|
Chen, S.,
Anderson, K.,
and Moore, M. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
593-598
|
| 38.
|
Aebi, M.,
Hornig, H.,
Padgett, R. A.,
Reiser, J.,
and Weissmann, C.
(1986)
Cell
47,
555-565
|
| 39.
|
Fu, X. Y.,
Colgan, J. D.,
and Manley, J. L.
(1988)
Mol. Cell. Biol.
8,
3582-3590
|
| 40.
|
Shea, C.,
Lee, M. G.,
and Van der Ploeg, L. H.
(1987)
Cell
50,
603-612
|
| 41.
|
Ulfendahl, P. J.,
Kreivi, J. P.,
and Akusjarvi, G.
(1989)
Nucleic Acids Res.
17,
925-938
|
| 42.
|
Frendewey, D.,
and Keller, W.
(1985)
Cell
42,
355-367
|
| 43.
|
Deshler, J. O.,
and Rossi, J. J.
(1991)
Genes Dev.
5,
1252-1263
|
| 44.
|
Solnick, D.
(1985)
Cell
43,
667-676
|
| 45.
|
Zorio, D. A.,
and Blumenthal, T.
(1999)
Nature
402,
835-838
|
| 46.
|
Wu, S.,
Romfo, C. M.,
Nilsen, T. W.,
and Green, M. R.
(1999)
Nature
402,
832-835
|
| 47.
|
Zamore, P. D.,
Patton, J. G.,
and Green, M. R.
(1992)
Nature
355,
609-614
|
| 48.
|
Valcarcel, J.,
Gaur, R. K.,
Singh, R.,
and Green, M. R.
(1996)
Science
273,
1706-1709
|
| 49.
|
Frank, D.,
Patterson, B.,
and Guthrie, C.
(1992)
Mol. Cell. Biol.
12,
5197-5205
|
| 50.
|
Chua, K.,
and Reed, R.
(1999)
Nature
402,
207-210
|
| 51.
|
Brys, A.,
and Schwer, B.
(1996)
RNA
2,
707-717
|
| 52.
|
Hodges, P. E.,
Jackson, S. P.,
Brown, J. D.,
and Beggs, J. D.
(1995)
Yeast
11,
337-342
|
| 53.
|
Umen, J. G.,
and Guthrie, C.
(1995)
Genes Dev.
9,
855-868
|
| 54.
|
Wyatt, J. R.,
Sontheimer, E. J.,
and Steitz, J. A.
(1992)
Genes Dev.
6,
2542-2553
|
| 55.
|
Teigelkamp, S.,
Newman, A. J.,
and Beggs, J. D.
(1995)
EMBO J.
14,
2602-2612
|
| 56.
|
Siatecka, M.,
Reyes, J. L.,
and Konarska, M. M.
(1999)
Genes Dev.
13,
1983-1993
|
| 57.
|
Achsel, T.,
Ahrens, K.,
Brahms, H.,
Teigelkamp, S.,
and Luhrmann, R.
(1998)
Mol. Cell. Biol.
18,
6756-6766
|
| 58.
|
Lucke, S.,
Klockner, T.,
Palfi, Z.,
Boshart, M.,
and Bindereif, A.
(1997)
EMBO J.
16,
4433-4440
|
| 59.
|
Langford, C. J.,
Klinz, F. J.,
Donath, C.,
and Gallwitz, D.
(1984)
Cell
36,
645-653
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. N. Siegel, K. S. W. Tan, and G. A. M. Cross
Systematic Study of Sequence Motifs for RNA trans Splicing in Trypanosoma brucei
Mol. Cell. Biol.,
November 1, 2005;
25(21):
9586 - 9594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ganot, T. Kallesoe, R. Reinhardt, D. Chourrout, and E. M. Thompson
Spliced-Leader RNA trans Splicing in a Chordate, Oikopleura dioica, with a Compact Genome
Mol. Cell. Biol.,
September 1, 2004;
24(17):
7795 - 7805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-h. Liang, A. Haritan, S. Uliel, and S. Michaeli
trans and cis Splicing in Trypanosomatids: Mechanism, Factors, and Regulation
Eukaryot. Cell,
October 1, 2003;
2(5):
830 - 840.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Manning-Cela, A. Gonzalez, and J. Swindle
Alternative Splicing of LYT1 Transcripts in Trypanosoma cruzi
Infect. Immun.,
August 1, 2002;
70(8):
4726 - 4728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Nepomuceno-Silva, K. Yokoyama, L. D. B. de Mello, S. M. Mendonca, J. C. Paixao, R. Baron, J.-C. Faye, F. S. Buckner, W. C. Van Voorhis, M. H. Gelb, et al.
TcRho1, a Farnesylated Rho Family Homologue from Trypanosoma cruzi. CLONING, TRANS-SPLICING, AND PRENYLATION STUDIES
J. Biol. Chem.,
August 3, 2001;
276(32):
29711 - 29718.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|